Brought to you by 
Cephalon publicly sells stock to net $288mm
28 May 2009
Executive Summary
Cephalon (cancer, neurology, and inflammatory disease therapeutics) has netted $288mm through the public offering of 5mm common shares at $60 each. The company concurrently sold 2.50% five-year senior subordinated notes (including the overallotment) netting $485mm. The notes convert into cash and shares at $69 each (or 14.49 shares per $1k).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon publicly sells stock to net $288mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice